{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:37:17Z","timestamp":1793137037743,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"DOI":"10.1186\/s13073-025-01445-5","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T10:24:09Z","timestamp":1742466249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications"],"prefix":"10.1186","volume":"17","author":[{"given":"Daniel J.","family":"Vis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander A. L.","family":"Palit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Corradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Cuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn P.","family":"Lolkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewyk F. A.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andries M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"6","key":"1445_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1445_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3322\/caac.21235","volume":"64","author":"CE DeSantis","year":"2014","unstructured":"DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252\u201371.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1445_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1186\/s12885-017-3617-6","volume":"17","author":"M Pascale","year":"2017","unstructured":"Pascale M, Azinwi CN, Marongiu B, Pesce G, Stoffel F, Roggero E. The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression. BMC Cancer. 2017;17(1):651.","journal-title":"BMC Cancer"},{"issue":"12","key":"1445_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S1470-2045(04)01641-9","volume":"5","author":"K Ahmad","year":"2004","unstructured":"Ahmad K. New progress in treatment of hormone-refractory prostate cancer. Lancet Oncol. 2004;5(12):706.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1445_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578\u201383.","journal-title":"Hum Pathol"},{"issue":"2","key":"1445_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68(2):325\u201334.","journal-title":"Eur Urol"},{"issue":"11","key":"1445_CR7","first-page":"974","volume":"28","author":"CG Drake","year":"2014","unstructured":"Drake CG. Visceral metastases and prostate cancer treatment: \u2018die hard\u2019, \u2018tough neighborhoods\u2019, or \u2018evil humors\u2019? Oncology (Williston Park). 2014;28(11):974\u201380.","journal-title":"Oncology (Williston Park)"},{"issue":"6","key":"1445_CR8","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1016\/j.clgc.2022.05.009","volume":"20","author":"AM Kase","year":"2022","unstructured":"Kase AM, Copland JA 3rd, Zhai Q, Tan W. Complete response in patients with lung-only metastatic prostate cancer: outcome analysis. Clin Genitourin Cancer. 2022;20(6):e485\u20139.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"1445_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.devcel.2019.04.012","volume":"49","author":"Y Gao","year":"2019","unstructured":"Gao Y, Bado I, Wang H, Zhang W, Rosen JM, Zhang XH. Metastasis organotropism: redefining the congenial soil. Dev Cell. 2019;49(3):375\u201391.","journal-title":"Dev Cell"},{"issue":"5","key":"1445_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","volume":"30","author":"Y Liu","year":"2016","unstructured":"Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell. 2016;30(5):668\u201381.","journal-title":"Cancer Cell"},{"issue":"2","key":"1445_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10555-010-9225-4","volume":"29","author":"G Pani","year":"2010","unstructured":"Pani G, Galeotti T, Chiarugi P. Metastasis: cancer cell\u2019s escape from oxidative stress. Cancer Metastasis Rev. 2010;29(2):351\u201378.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"1445_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semcancer.2011.01.002","volume":"21","author":"H Peinado","year":"2011","unstructured":"Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011;21(2):139\u201346.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"1445_CR13","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/ijc.29839","volume":"138","author":"GF Weber","year":"2016","unstructured":"Weber GF. Metabolism in cancer metastasis. Int J Cancer. 2016;138(9):2061\u20136.","journal-title":"Int J Cancer"},{"issue":"4","key":"1445_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.eururo.2013.05.029","volume":"64","author":"CE Barbieri","year":"2013","unstructured":"Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Gronberg H, et al. The mutational landscape of prostate cancer. Eur Urol. 2013;64(4):567\u201376.","journal-title":"Eur Urol"},{"issue":"7547","key":"1445_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353\u20137.","journal-title":"Nature"},{"issue":"11","key":"1445_CR16","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/ng.3419","volume":"47","author":"MM Pomerantz","year":"2015","unstructured":"Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M, et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015;47(11):1346\u201351.","journal-title":"Nat Genet"},{"issue":"1","key":"1445_CR17","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1038\/s41467-018-07270-2","volume":"9","author":"S Stelloo","year":"2018","unstructured":"Stelloo S, Nevedomskaya E, Kim Y, Schuurman K, Valle-Encinas E, Lobo J, et al. Integrative epigenetic taxonomy of primary prostate cancer. Nat Commun. 2018;9(1):4900.","journal-title":"Nat Commun"},{"issue":"6","key":"1445_CR18","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ccell.2019.10.005","volume":"36","author":"P Mazrooei","year":"2019","unstructured":"Mazrooei P, Kron KJ, Zhu Y, Zhou S, Grillo G, Mehdi T, et al. Cistrome partitioning reveals convergence of somatic mutations and risk variants on master transcription regulators in primary prostate tumors. Cancer Cell. 2019;36(6):674-89 e6.","journal-title":"Cancer Cell."},{"issue":"8","key":"1445_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","volume":"52","author":"MM Pomerantz","year":"2020","unstructured":"Pomerantz MM, Qiu X, Zhu Y, Takeda DY, Pan W, Baca SC, et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020;52(8):790\u20139.","journal-title":"Nat Genet"},{"issue":"1","key":"1445_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13148-022-01278-8","volume":"14","author":"T Severson","year":"2022","unstructured":"Severson T, Qiu X, Alshalalfa M, Sjostrom M, Quigley D, Bergman A, et al. Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer. Clin Epigenetics. 2022;14(1):60.","journal-title":"Clin Epigenetics"},{"issue":"11","key":"1445_CR21","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.15252\/emmm.201505424","volume":"7","author":"S Stelloo","year":"2015","unstructured":"Stelloo S, Nevedomskaya E, van der Poel HG, de Jong J, van Leenders GJ, Jenster G, et al. Androgen receptor profiling predicts prostate cancer outcome. EMBO Mol Med. 2015;7(11):1450\u201364.","journal-title":"EMBO Mol Med"},{"issue":"6","key":"1445_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487\u201395.","journal-title":"Cancer Discov"},{"issue":"3","key":"1445_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41391-021-00332-5","volume":"24","author":"JE Berchuck","year":"2021","unstructured":"Berchuck JE, Viscuse PV, Beltran H, Aparicio A. Clinical considerations for the management of androgen indifferent prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):623\u201337.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1445_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","volume":"121","author":"V Conteduca","year":"2019","unstructured":"Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019;121:7\u201318.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1445_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298\u2013305.","journal-title":"Nat Med"},{"issue":"9","key":"1445_CR26","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1158\/2159-8290.CD-21-0576","volume":"12","author":"S Linder","year":"2022","unstructured":"Linder S, Hoogstraat M, Stelloo S, Eickhoff N, Schuurman K, de Barros H, et al. Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer toward androgen independence. Cancer Discov. 2022;12(9):2074\u201397.","journal-title":"Cancer Discov"},{"issue":"16","key":"1445_CR27","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-23-0593","volume":"83","author":"A Lundberg","year":"2023","unstructured":"Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, et al. The genomic and epigenomic landscape of double-negative metastatic prostate cancer. Cancer Res. 2023;83(16):2763\u201374.","journal-title":"Cancer Res"},{"issue":"2","key":"1445_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline\u00a0(version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer."},{"issue":"1","key":"1445_CR29","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1038\/s41467-019-13084-7","volume":"10","author":"LF van Dessel","year":"2019","unstructured":"van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, et al. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat Commun. 2019;10(1):5251.","journal-title":"Nat Commun"},{"issue":"7781","key":"1445_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","volume":"575","author":"P Priestley","year":"2019","unstructured":"Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575(7781):210\u20136.","journal-title":"Nature"},{"issue":"7","key":"1445_CR31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jmoldx.2021.04.011","volume":"23","author":"P Roepman","year":"2021","unstructured":"Roepman P, de Bruijn E, van Lieshout S, Schoenmaker L, Boelens MC, Dubbink HJ, et al. Clinical validation of whole genome sequencing for cancer diagnostics. J Mol Diagn. 2021;23(7):816\u201333.","journal-title":"J Mol Diagn"},{"issue":"1","key":"1445_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13073-018-0539-0","volume":"10","author":"F Blokzijl","year":"2018","unstructured":"Blokzijl F, Janssen R, van Boxtel R, Cuppen E. MutationalPatterns: comprehensive genome-wide analysis of mutational processes. Genome Med. 2018;10(1):33.","journal-title":"Genome Med"},{"issue":"2","key":"1445_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s43018-020-0027-5","volume":"1","author":"A Degasperi","year":"2020","unstructured":"Degasperi A, Amarante TD, Czarnecki J, Shooter S, Zou X, Glodzik D, et al. A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies. Nat Cancer. 2020;1(2):249\u201363.","journal-title":"Nat Cancer"},{"issue":"3","key":"1445_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen B, Fong C, Luthra A, Smith SA, DiNatale RG, Nandakumar S, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022;185(3):563-75 e11.","journal-title":"Cell."},{"key":"1445_CR35","doi-asserted-by":"crossref","unstructured":"Benjamini YH, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Statist Soc. 1995:57(1):289\u2013300.","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"issue":"2","key":"1445_CR36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41391-021-00486-2","volume":"25","author":"M Alshalalfa","year":"2022","unstructured":"Alshalalfa M, Seldon C, Franco I, Vince R, Carmona R, Punnen S, et al. Clinicogenomic characterization of prostate cancer liver metastases. Prostate Cancer Prostatic Dis. 2022;25(2):366\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"1445_CR37","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/ejn.14620","volume":"51","author":"R Gao","year":"2020","unstructured":"Gao R, Pratt CP, Yoon S, Martin-de-Saavedra MD, Forrest MP, Penzes P. CNTNAP2 is targeted to endosomes by the polarity protein PAR3. Eur J Neurosci. 2020;51(4):1074\u201386.","journal-title":"Eur J Neurosci"},{"key":"1445_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41525-020-0122-7","volume":"5","author":"ZJ Zhou","year":"2020","unstructured":"Zhou ZJ, Luo CB, Xin HY, Hu ZQ, Zhu GQ, Li J, et al. MACROD2 deficiency promotes hepatocellular carcinoma growth and metastasis by activating GSK-3beta\/beta-catenin signaling. NPJ Genom Med. 2020;5:15.","journal-title":"NPJ Genom Med"},{"issue":"2","key":"1445_CR39","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/sj.pcan.4500573","volume":"5","author":"H Nakamachi","year":"2002","unstructured":"Nakamachi H, Suzuki H, Akakura K, Imamoto T, Ueda T, Ishihara M, et al. Clinical significance of pulmonary metastases in stage D2 prostate cancer patients. Prostate Cancer Prostatic Dis. 2002;5(2):159\u201363.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"1445_CR40","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","volume":"65","author":"C Pezaro","year":"2014","unstructured":"Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65(2):270\u20133.","journal-title":"Eur Urol"},{"issue":"670","key":"1445_CR41","doi-asserted-by":"publisher","first-page":"eabn7336","DOI":"10.1126\/scitranslmed.abn7336","volume":"14","author":"IY Jung","year":"2022","unstructured":"Jung IY, Narayan V, McDonald S, Rech AJ, Bartoszek R, Hong G, et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Sci Transl Med. 2022;14(670):eabn7336.","journal-title":"Sci Transl Med."},{"issue":"2\u20133","key":"1445_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10555-013-9471-3","volume":"33","author":"MA Augello","year":"2014","unstructured":"Augello MA, Den RB, Knudsen KE. AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev. 2014;33(2\u20133):399\u2013411.","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"1445_CR43","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575\u201386.","journal-title":"Cancer Cell"},{"key":"1445_CR44","doi-asserted-by":"crossref","unstructured":"Schiewer MJ, Knudsen KE. DNA damage response in prostate cancer.\u00a0Cold Spring Harb Perspect Med. 2019;9(1):a030486.","DOI":"10.1101\/cshperspect.a030486"},{"issue":"1","key":"1445_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11\u201322.","journal-title":"Cancer Cell"},{"key":"1445_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-3-030-32656-2_16","volume":"1210","author":"Y Yeh","year":"2019","unstructured":"Yeh Y, Guo Q, Connelly Z, Cheng S, Yang S, Prieto-Dominguez N, et al. Wnt\/beta-catenin signaling and prostate cancer therapy resistance. Adv Exp Med Biol. 2019;1210:351\u201378.","journal-title":"Adv Exp Med Biol"},{"key":"1445_CR47","unstructured":"Cancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell. 2015:163(4):1011\u201325."},{"issue":"4","key":"1445_CR48","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1172\/JCI132031","volume":"130","author":"J Mateo","year":"2020","unstructured":"Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest. 2020;130(4):1743\u201351.","journal-title":"J Clin Invest"},{"issue":"10","key":"1445_CR49","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/ERC-22-0140","volume":"29","author":"M Shiota","year":"2022","unstructured":"Shiota M, Akamatsu S, Tsukahara S, Nagakawa S, Matsumoto T, Eto M. Androgen receptor mutations for precision medicine in prostate cancer. Endocr Relat Cancer. 2022;29(10):R143\u201355.","journal-title":"Endocr Relat Cancer"},{"key":"1445_CR50","doi-asserted-by":"crossref","unstructured":"Khosh Kish E, Choudhry M, Gamallat Y, Buharideen SM, D D, Bismar TA. The expression of proto-oncogene ETS-related gene (ERG) plays a central role in the oncogenic mechanism involved in the development and progression of prostate cancer.\u00a0Int J Mol Sci. 2022;23(9):4772.","DOI":"10.3390\/ijms23094772"},{"issue":"12","key":"1445_CR51","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10(12):1808\u201325.","journal-title":"Cancer Discov"},{"issue":"7463","key":"1445_CR52","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321.","journal-title":"Nature"},{"issue":"10","key":"1445_CR53","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1172\/JCI121924","volume":"128","author":"D Nava Rodrigues","year":"2018","unstructured":"Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018;128(10):4441\u201353.","journal-title":"J Clin Invest"},{"issue":"12","key":"1445_CR54","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1158\/0008-5472.CAN-21-0688","volume":"81","author":"A Chang","year":"2021","unstructured":"Chang A, Liu L, Ashby JM, Wu D, Chen Y, O\u2019Neill SS, et al. Recruitment of KMT2C\/MLL3 to DNA damage sites mediates DNA damage responses and regulates PARP inhibitor sensitivity in cancer. Cancer Res. 2021;81(12):3358\u201373.","journal-title":"Cancer Res"},{"key":"1445_CR55","doi-asserted-by":"crossref","unstructured":"Rampias T, Karagiannis D, Avgeris M, Polyzos A, Kokkalis A, Kanaki Z, et al. The lysine-specific methyltransferase KMT2C\/MLL3 regulates DNA repair components in cancer.\u00a0EMBO Rep. 2019;20(3):e46821.","DOI":"10.15252\/embr.201846821"},{"issue":"3","key":"1445_CR56","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1101\/gad.292516.116","volume":"31","author":"JW Leung","year":"2017","unstructured":"Leung JW, Makharashvili N, Agarwal P, Chiu LY, Pourpre R, Cammarata MB, et al. ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair. Genes Dev. 2017;31(3):260\u201374.","journal-title":"Genes Dev"},{"issue":"4","key":"1445_CR57","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/path.5912","volume":"257","author":"CD Steele","year":"2022","unstructured":"Steele CD, Pillay N, Alexandrov LB. An overview of mutational and copy number signatures in human cancer. J Pathol. 2022;257(4):454\u201365.","journal-title":"J Pathol"},{"issue":"4","key":"1445_CR58","first-page":"2707","volume":"19","author":"X Zhao","year":"2019","unstructured":"Zhao X, Lei Y, Li G, Cheng Y, Yang H, Xie L, et al. Integrative analysis of cancer driver genes in prostate adenocarcinoma. Mol Med Rep. 2019;19(4):2707\u201315.","journal-title":"Mol Med Rep"},{"issue":"1","key":"1445_CR59","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.eururo.2019.05.032","volume":"77","author":"P Isaacsson Velho","year":"2020","unstructured":"Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, et al. Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer. Eur Urol. 2020;77(1):14\u201321.","journal-title":"Eur Urol"},{"issue":"10","key":"1445_CR60","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1158\/1535-7163.MCT-08-0494","volume":"7","author":"Y Lu","year":"2008","unstructured":"Lu Y, Nie D, Witt WT, Chen Q, Shen M, Xie H, et al. Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3 beta phosphorylation. Mol Cancer Ther. 2008;7(10):3203\u201311.","journal-title":"Mol Cancer Ther"},{"issue":"369","key":"1445_CR61","doi-asserted-by":"crossref","first-page":"369ra177","DOI":"10.1126\/scitranslmed.aai9188","volume":"8","author":"LC van Kempen","year":"2016","unstructured":"van Kempen LC, Redpath M, Elchebly M, Klein KO, Papadakis AI, Wilmott JS, et al. The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. Sci Transl Med. 2016;8(369):369ra177.","journal-title":"Sci Transl Med."},{"issue":"3","key":"1445_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc3878","volume":"15","author":"HT Lynch","year":"2015","unstructured":"Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895\u20132015. Nat Rev Cancer. 2015;15(3):181\u201394.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"1445_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176181","volume":"12","author":"LA Albacker","year":"2017","unstructured":"Albacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS ONE. 2017;12(11): e0176181.","journal-title":"PLoS ONE"},{"issue":"1","key":"1445_CR64","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41698-018-0047-0","volume":"2","author":"W Chen","year":"2018","unstructured":"Chen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ Precis Oncol. 2018;2(1):4.","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"1445_CR65","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrc2795","volume":"10","author":"GP Risbridger","year":"2010","unstructured":"Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer. 2010;10(3):205\u201312.","journal-title":"Nat Rev Cancer"},{"key":"1445_CR66","doi-asserted-by":"crossref","unstructured":"Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.\u00a0JCI Insight. 2019;4(6):e126908.","DOI":"10.1172\/jci.insight.126908"},{"issue":"4","key":"1445_CR67","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","volume":"5","author":"W Abida","year":"2019","unstructured":"Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5(4):471\u20138.","journal-title":"JAMA Oncol"},{"key":"1445_CR68","doi-asserted-by":"crossref","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015:348(6230):124\u20138.","DOI":"10.1126\/science.aaa1348"},{"issue":"1","key":"1445_CR69","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44\u201356.","journal-title":"Ann Oncol"},{"issue":"5","key":"1445_CR70","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38(5):395\u2013405.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1445_CR71","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700\u201312.","journal-title":"Lancet Oncol"},{"key":"1445_CR72","doi-asserted-by":"crossref","unstructured":"Petrylak DP, Ratta R, Matsubara N, Korbenfeld EP, Gafanov R, Mourey L, et al. Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): randomized, double-blind, phase 3 KEYNOTE-921 study. J Clin Oncol. 2023:41(6_suppl):19-.","DOI":"10.1200\/JCO.2023.41.6_suppl.19"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01445-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-025-01445-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01445-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T09:32:50Z","timestamp":1742549570000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-025-01445-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1186\/s13073-025-01445-5","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients with metastatic disease, including prostate cancer, were included in the CPCT-02 (NCT01855477) metastatic site biopsy study, which was approved by the Medical Ethical Committee of the University Medical Center Utrecht, the Netherlands and was conducted following the Declaration of Helsinki. All patients explicitly consented to WGS and data sharing for cancer research purposes. WGS and clinical data, including primary tumor type and biopsy location, were collected in electronic case record forms and stored in a central database by Hartwig.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors declared any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}